Equities Analysts Issue Forecasts for TCRX FY2025 Earnings

TScan Therapeutics, Inc. (NASDAQ:TCRX) – Equities researchers at HC Wainwright raised their FY2025 EPS estimates for TScan Therapeutics in a research note issued on Thursday, November 13th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings of ($1.05) per share for the year, up from their prior estimate of ($1.17). HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.12) per share. HC Wainwright also issued estimates for TScan Therapeutics’ Q4 2025 earnings at ($0.23) EPS, Q1 2026 earnings at ($0.20) EPS, Q2 2026 earnings at ($0.22) EPS, Q3 2026 earnings at ($0.23) EPS, Q4 2026 earnings at ($0.24) EPS, FY2026 earnings at ($0.88) EPS, FY2027 earnings at ($0.89) EPS, FY2028 earnings at ($0.80) EPS and FY2029 earnings at ($0.47) EPS.

TScan Therapeutics (NASDAQ:TCRX) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.07. TScan Therapeutics had a negative return on equity of 73.33% and a negative net margin of 1,692.96%.The business had revenue of $2.51 million during the quarter, compared to the consensus estimate of $1.98 million.

Several other research firms have also recently commented on TCRX. Needham & Company LLC decreased their target price on TScan Therapeutics from $9.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, November 4th. Morgan Stanley downgraded shares of TScan Therapeutics from an “overweight” rating to an “equal weight” rating in a research report on Friday. BTIG Research downgraded shares of TScan Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday, November 4th. Wedbush reiterated an “outperform” rating and issued a $7.00 target price on shares of TScan Therapeutics in a report on Tuesday, August 12th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of TScan Therapeutics in a research report on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $6.60.

TScan Therapeutics Stock Performance

NASDAQ:TCRX opened at $1.10 on Monday. The company has a 50 day simple moving average of $1.84 and a two-hundred day simple moving average of $1.70. The company has a debt-to-equity ratio of 0.23, a quick ratio of 6.44 and a current ratio of 6.44. TScan Therapeutics has a fifty-two week low of $1.02 and a fifty-two week high of $4.94. The company has a market capitalization of $62.43 million, a PE ratio of -0.98 and a beta of 1.00.

Institutional Investors Weigh In On TScan Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Catalyst Funds Management Pty Ltd bought a new stake in TScan Therapeutics in the 2nd quarter valued at about $26,000. Vanguard Personalized Indexing Management LLC bought a new position in TScan Therapeutics during the second quarter worth about $29,000. Quadrature Capital Ltd purchased a new position in shares of TScan Therapeutics in the second quarter worth about $33,000. Boothbay Fund Management LLC raised its position in shares of TScan Therapeutics by 50.0% in the second quarter. Boothbay Fund Management LLC now owns 24,363 shares of the company’s stock valued at $35,000 after purchasing an additional 8,121 shares during the period. Finally, Hsbc Holdings PLC bought a new stake in shares of TScan Therapeutics in the first quarter valued at approximately $49,000. Hedge funds and other institutional investors own 82.83% of the company’s stock.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.